REGISTERED
on 16 Mar 2021
Last Applicant/ Owned by
6-1, Marunouchi 2-chome Chiyoda-ku
Tokyo
JP
100-8086
Serial Number
88835276 filed on 16th Mar 2020
Registration Number
6292309 registered on 16th Mar 2021
Correspondent Address
Tomoko Nakajima
Filing Basis
No Filing Basis
Disclaimer
NO DATA
PEPTIGROWTH
Testing, inspection, evaluation or research of pharmaceuticals; Information services relating to testing, inspection, evaluation or research of pharmaceuticals; Scientific laboratory services, namely, Testing, inspection, research or development of cell, tissue culture; Scientific Information services relating to testing, inspection, research or development of cell, tissue culture; Testing, inspec Read More
Classification Information
Class [042]
Computer & Software Services & Scientific Services
Testing, inspection, evaluation or research of pharmaceuticals; Information services relating to testing, inspection, evaluation or research of pharmaceuticals; Scientific laboratory services, namely, Testing, inspection, research or development of cell, tissue culture; Scientific Information services relating to testing, inspection, research or development of cell, tissue culture; Testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs; Pharmaceutical research services; Pharmaceutical research; Research in the pharmaceutical field; Testing, inspection or research of pharmaceuticals, cosmetics
Class [040]
Treatment & Processing of Materials Services
Commissioning manufacture of synthetic peptides being contract manufacturing in the field of synthetic peptides; Custom manufacture of synthetic peptides; Custom manufacture of pharmaceuticals; Custom manufacture of chemicals
Class [035]
Advertising, Business & Retail Services
Retail store services and wholesale store services for chemicals; Retail store services and wholesale store services for pharmaceutical drugs
Class [005]
Pharmaceutical Products
Synthetic peptides for pharmaceutical purposes, namely, for the treatment of cancer, infectious diseases, and diseases and disorders related to the central nervous system, musculoskeletal system, cardiovascular system, endocrine system, metabolic system, immunological system, skin, blood, ocular system, urological system, genital system, digestive system, respiratory system, and autoimmune system, using regenerative medicine, cell therapy, antibody drug and gene therapy; Chemical preparations for pharmaceutical purposes, namely, for the treatment of cancer, infectious diseases, and diseases and disorders related to the central nervous system, musculoskeletal system, cardiovascular system, endocrine system, metabolic system, immunological system, skin, blood, ocular system, urological system, genital system, digestive system, respiratory system, and autoimmune system, using regenerative medicine, cell therapy, antibody drug and gene therapy; Peptides dietary supplements in the form of granular, tablet, powdery, liquid, gels, capsules; Dietary supplements
Class [001]
Chemical Products
Chemicals for use in industry; Chemicals for use in the manufacture of pharmaceuticals; Chemicals, namely, peptide for use in the manufacture of pharmaceuticals
Mark Details
Serial Number
No 88835276
Mark Type
No Service Mark
Attorney Docket Number
No 1012-0035
44D Filed
Yes
44D Current
No
44E filed
No
44E Current
Yes
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 02th Apr 2024 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| 02th Apr 2024 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| 02th Apr 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| 16th Mar 2021 | REGISTERED-PRINCIPAL REGISTER |
| 02th Mar 2021 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| 02th Mar 2021 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| 02th Mar 2021 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| 11th Feb 2021 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| 11th Feb 2021 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| 11th Feb 2021 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |